ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant...
11 insider purchases on record · latest filing 2025-06-23.
Insiders have also filed 119 sale transactions at ORIC.